Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Vanguard Mega Cap Growth ETF (MGK) Price & Performance

BridgeBio Pharma IncTrade
Vanguard Mega Cap Growth ETFTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Vanguard Mega Cap Growth ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Vanguard Mega Cap Growth ETF trades at $91.07. Which is the better fit depends on your goals.

BBIOMGK
Market Cap
$16.36B
Sector
HealthBroad Market / Factor
52-Week High
$90.17$92.06
52-Week Low
$47.29$70.70
Enterprise Value
$18.14B

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Vanguard Mega Cap Growth ETF

MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.

Read more on MGK